α-TEA in Advanced Cancer
Public ClinicalTrials.gov record NCT02192346. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase I Study of Alpha-tocopheryloxyacetic Acid (α-TEA) in Patients With Advanced Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this study is to find the highest dose of α-TEA that can be given to patients safely, to identify potential side effects of α-TEA, and to measure the amount of α-TEA in patients' blood. Additional goals of this study are to monitor the effect on tumors, to check for specific immune cells circulating in the blood, and to see if there are certain features of tumors that make it possible to predict the response to α-TEA.
Study identification
- NCT ID
- NCT02192346
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 17 participants
Conditions and interventions
Interventions
- 2.4 mg/kg α-TEA Drug
- 4.8 mg/kg α-TEA Drug
- 8.0 mg/kg α-TEA Drug
- 9.6 mg/kg α-TEA Drug
- 12 mg/kg α-TEA Drug
- 16.8 mg/kg α-TEA Drug
- 19.2 mg/kg α-TEA Drug
- 22.3 mg/kg α-TEA Drug
- 26.8 mg/kg α-TEA Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 4, 2014 (Actual)
- Primary completion
- Dec 11, 2017 (Actual)
- Completion
- May 8, 2018 (Actual)
- Last update posted
- Aug 17, 2018
2014 – 2018
United States locations
- U.S. sites
- 5
- U.S. states
- 1
- U.S. cities
- 4
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Oncology & Hematology Care Clinic- Southeast | Clackamas | Oregon | 97015 | — |
| Providence Oncology & Hematoloty Care Clinic- Newberg | Newberg | Oregon | 97132 | — |
| Providence Oncology & Hematology Care Clinic- Willamette Falls | Oregon City | Oregon | 97045 | — |
| Providence Oncology & Hematology Care Clinic- Eastside | Portland | Oregon | 97213 | — |
| Providence Oncology & Hematology Care Clinic- Westside | Portland | Oregon | 97225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02192346, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 17, 2018 · Synced Oct 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02192346 live on ClinicalTrials.gov.